Key result
In a rat model of bupivacaine toxicity, central continuous infusion and peripheral bolus injections of lipid emulsion yielded higher survival than peripheral continuous infusion.
Why the study?
Does the locus and mode of intravenous lipid emulsion delivery improve survival in rats with bupivacaine toxicity?
Does the locus and mode of intravenous lipid emulsion delivery improve survival in rats with bupivacaine toxicity?
Answers are grounded in this paper and cite their sources.
Central continuous infusion or peripheral bolus injections of lipid emulsion appear more effective than peripheral continuous infusion for reversing bupivacaine-induced asystole in a rat model.
In standard clinical anesthesia practice, critical adverse events rarely occur. This is particularly true for local and regional anesthesia, with drugs safely applied in the periphery, or neuraxis, and normally only minor systemic distribution. However, despite the use of modern techniques, such as intraoperative ultrasound, accidental intravenous injections or cumulative overdosing does occur, leading to Local Anesthetic Systemic Toxicity (LAST).1 Bupivacaine is one of the most toxic local anesthetics when present in the systemic circulation. Such toxicity results from both its inherent potency at the toxic sites of action (see below) and from the very slow, often incomplete recovery during resuscitation; both aspects may result from bupivacaine’s greater lipophilicity. Until recently, these accidents were often fatal despite heroic efforts at cardiopulmonary resuscitation and multiple doses of epinephrine, but a serendipitous discovery in laboratory rats introduced the concept of lipid emulsion therapy. Now, in situations where blood levels of bupivacaine (or any other toxic lipophilic/amphipathic drug) become dangerously high, prompt delivery of intravenous lipid emulsions (ILEs, eg, Intralipid [Baxter Healthcare Corp, Deerfield, IL]) most often rapidly reverses or prevents any pathophysiological occurrences.2–4 Today almost every hospital operating room that delivers local anesthesia has such Intralipid for rescue readily at hand, and we hope that free-standing surgical sites are equally well prepared for these adverse events. The mechanisms of systemic bupivacaine toxicity are complex. Direct effects on cardiac,5 vascular,6 and brain tissues7 and peripheral nerve8 have been documented in experimental animals, with central nervous system (CNS) actions contributing to the cardiac dysrhythmias arising from direct actions on the heart.9 Effects on ion channels, including those voltage-gated proteins that passively conduct Na+,10 K+,11 and Ca+2,12 can explain some of the rhythm disturbances, but ample evidence suggests that signal transduction pathways, starting with G protein-coupled receptors13 but possibly including more “downstream” steps,14 are also directly affected. One important target for toxicity appears to be metabolic pathways, with mitochondrial oxidative phosphorylation known to be inhibited in isolated tissues and in vivo.15,16 Correspondingly, there are 2 general mechanisms by which lipid infusion is hypothesized to reverse LAST.17–19 One, the lipid sink hypothesis, states that lipid emulsion in the blood sequesters the lipophilic drug molecules, reducing the concentration of “free” drug and thus promoting the dissociation of drug that is bound to the intoxicated tissues.20 Lipid-bound drug is then metabolized by the liver (and possibly other organs) and the products eliminated. Ample experimental (rat) evidence supports this theory, with direct measures showing that lipid infusion lowers the toxic blood and tissue levels of experimentally infused animals21–23 and can shift rightward the toxic dose–response curves.24 However, human volunteer studies with subtoxic levels of bupivacaine25 and studies in pigs made hypoxic,26 as occurs clinically during asystole, failed to show these effects of lipid infusion. The second general mechanism proposes that the metabolic depression from bupivacaine is reversed by actions of the lipid triglyceride molecules.27,28 These molecules, and some of their metabolites, can provide an energy source that can overcome metabolic depression in the substrate-limited metabolism of an intoxicated heart (and possibly brain).29 Experimental animal evidence also supports this theory, with the composition of the lipid in the emulsion having importance in keeping with its metabolic utility.30 It appears likely that both mechanisms contribute to the reversal of symptoms by ILE,17 and their relative values may depend on the concentration of plasma bupivacaine, the pattern of toxicity by it (and by other intoxicating drugs), and the patient’s physiological status.31 It is noteworthy that the greater toxicity of local anesthetics correlates with their greater lipophilicity, but only the lipid sink hypothesis, and not the metabolic one, depends on the drugs’ lipophilicity. Given this broad array of potential targets for bupivacaine toxicity, what improvements can be made in the development of ILEs and in their delivery? In this issue of Anesthesia & Analgesia, Liu et al32 report the results of varying the locus and mode of ILE delivery on intentional bupivacaine toxicity in rats. They used 3 regimens to deliver 20% ILE: (1) “central (internal jugular) continuous infusion,” (2) “peripheral (tail vein) continuous infusion,” or (3) “peripheral (tail vein) bolus injections,” all in initially anesthetized (sevoflurane) and intensively monitored rats. Immediately after sevoflurane was discontinued, the rats received 0.2% bupivacaine through a femoral vein catheter to rapidly reach 20 mg·kg−1, which quickly led to asystole, at which point either continuous infusion or the first bolus injection of lipid emulsion began. The infusions/injections were accompanied by repeated chest compressions for ≤40 minutes, mimicking the standard clinical situation wherein cardiopulmonary resuscitation should be continued during ILE rescue attempts. Both arterial blood samples (taken at 40 minutes after bupivacaine) and myocardial tissue samples (from hearts of rats euthanized at the study end) were analyzed for bupivacaine levels. The survival rates were 80% for the central infusion group (group 1), 73% for the peripheral bolus group (group 3), but significantly lower, only 20%, for the peripheral infusion group (group 2). Heartbeat returned in 100% (group 1), 67% (group 3), and 86% (group 2) of rats, showing that return of cardiac excitability per se was not an indicator of survival. Other hemodynamic parameters recovered faster in groups 1 and 3 than in the rats with continuous peripheral infusion (group 2). Plasma and myocardial tissue levels of bupivacaine were lower in the better surviving groups. The strength of this article is in the number and integration of several important parameters of bupivacaine toxicity; both intraepisodic hemodynamic measurements and ultimate survival are combined with measured levels of bupivacaine in serum and in the heart. It would have been even better if brain tissue had also been assayed given the involvement of the CNS in cardiac toxicity. One notable weakness in this study is the use of the rodent heart, which is too small to allow the long cardiac conduction pathway that enables the circus rhythms that are a common cause of ventricular fibrillations.33 How might these experimental rodent results alter our clinical practice? Current guidelines33 based primarily on rat experiments indicate the use of 20% lipid emulsion (eg, Intralipid 1) administered as a 1.5-mL/kg bolus over 2–3 minutes followed immediately by a continuous infusion of 20% lipid emulsion at a rate of 0.25 mL/kg/min. Within the guidelines, there is the option to give another bolus should the initial attempt fail to produce the desired effect; the continuous peripheral infusion rate can be doubled to 0.5 mL/kg/min if blood pressure remains low and should continue for ≥10 minutes after attaining circulatory stability. The current guidelines result from 2 important animal studies.24,34 (The concentration of Intralipid [20%] is based on its toxicity-reversing effect as well as the risk of complication, with reported adverse events including dyspnea, cyanosis, flushing, hypercoagulability, hypertriglyceridemia, and chest pain.35,36 Whether these complications occur more often during continuous infusions versus bolus injections is not known, but such information might suggest an alteration in the concentration of ILE used for resuscitation.) Because the lipid emulsion may need to reach its site of action almost immediately to be effective, as a lipid sink or metabolic effect, the choice of the route of administration of the lipid emulsion is critical. Centrally administered medications should reach peak concentrations in the heart and brain with significantly shorter lag times than peripheral administrations.37 This peak effect may also be achieved by the multiple boluses. This finding suggests that there is room to improve how we administer the lipid emulsion to increase its efficacy. Not all patients will have central access, but the administration of multiple boluses of lipid emulsion via peripheral access may substitute for central administration. In addition, we still have room to improve on early identification of patients who are experiencing early signs of LAST. In such cases, should we start a lipid emulsion earlier and would we avoid an arrhythmia or seizure? However, the prodromal early signs of LAST, including tinnitus, metallic taste, and perioral numbness,38 are not as frequently reported as we would expect. A review of 93 cases of LAST reported between 1979 and 2009 indicated that these signs accounted for only 18% of reported CNS symptoms and only occurred in 15 of the 93 patients.31 The majority of these patients presented with CNS, cardiovascular, or a combination of the 2 toxicities, patterns that probably depend on the site and rate of bupivacaine administration. This present study comes at an interesting time, when more local anesthetic use is considered to manage patients’ pain intraoperatively as the primary anesthetic or for perioperative pain management. The growing interest in the use of local anesthetics in recent years has been in part due to the development of enhanced recovery after surgery pathways and a national trend in minimizing the use of opioids. More emphasis has been placed on the use of local anesthetics this past year as a component of multimodal pain management due to a decreased supply of intravenous opioids and the opioid abuse crisis in the United States. Consequently, at our institution, there has been a notable increase in the use of local infiltration by surgeons and for neuraxial and peripheral nerve blocks for perioperative pain relief (10% over 3 years). Accompanying this greater exposure to local anesthetics is a likely parallel increase in cases of local anesthetic toxicity. Although we have not found the ideal antidote for LAST, there is a case-tested treatment. Now, we should focus on improvements in the composition of ILEs and on the ways and when we administer them to optimize their use in saving lives. ACKNOWLEDGMENTS The authors thank Ms Claire Bejgrowicz for excellent secretarial assistance and Dr Philipp Lirk, MD, PhD, for critical reading of the manuscript. DISCLOSURES Name: José Luis Zeballos, MD. Contribution: This author helped write the editorial. Name: Gary R. Strichartz, PhD. Contribution: This author helped write the editorial. This manuscript was handled by: Markus W. Hollmann, MD, PhD.
No takes yet. Share an insight, caveat, or question.
Zeballos et al. (2019) conducted an editorial in Local Anesthetic Systemic Toxicity (LAST). Intravenous lipid emulsions (ILE) was evaluated on Survival rates. In a rat model of bupivacaine toxicity, central continuous infusion and peripheral bolus injections of lipid emulsion yielded higher survival than peripheral continuous infusion.
Synapse has enriched 10 related papers. Consider them for comparative context: